Tobin C. Schilke
Net Worth
Last updated:
What is Tobin C. Schilke net worth?
The estimated net worth of Mr. Tobin C. Schilke is at least $3,462,578 as of 3 Jul 2023. He owns shares worth $291,620 as insider, has earned $2,018,778 from insider trading and has received compensation worth at least $1,152,180 in Revance Therapeutics, Inc..
What is the salary of Tobin C. Schilke?
Mr. Tobin C. Schilke salary is $576,090 per year as Chief Financial Officer & Principal Accounting Officer in Revance Therapeutics, Inc..
How old is Tobin C. Schilke?
Mr. Tobin C. Schilke is 50 years old, born in 1975.
What stocks does Tobin C. Schilke currently own?
As insider, Mr. Tobin C. Schilke owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) | Chief Financial Officer & Principal Accounting Officer | 79,896 | $3.65 | $291,620 |
What does Revance Therapeutics, Inc. do?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Tobin C. Schilke insider trading
Revance Therapeutics, Inc.
Mr. Tobin C. Schilke has made 13 insider trades in 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,701 units of RVNC stock worth $42,593 on 3 Jul 2023.
The largest trade he's ever made was exercising 21,401 units of RVNC stock on 15 May 2023. As of 3 Jul 2023 he still owns at least 79,896 units of RVNC stock.
Revance Therapeutics key executives
Revance Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Abhay Joshi (62) Chief Operating Officer, Pres of R&D and Product Operations
- Mr. Dustin S. Sjuts (46) Pres
- Mr. Dwight Moxie (48) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Mark J. Foley (60) Chief Executive Officer & Director
- Mr. Tobin C. Schilke (50) Chief Financial Officer & Principal Accounting Officer